A fiduciary is someone legally and ethically bound to act in another party's best interest, even when their own interests would suggest otherwise. In the context of pharmacy benefits, a fiduciary consultant accepts no compensation from PBMs, drug manufacturers, specialty pharmacies, or any other vendor, only from the plan sponsor that hires them. That compensation structure removes the conflicts of interest that compromise most traditional pharmacy advice.
The fiduciary distinction matters because the alternative is so common. Most "pharmacy consultants" working with self-insured employers today are brokers who hold a broker-of-record relationship with one or more PBMs. Under that arrangement, the PBM pays the broker a commission, sometimes 5% or more of the plan's total pharmacy spend, often disclosed as a "Broker Override Fee" or "Administrative Fee" that the plan sponsor doesn't directly see. The broker has a financial incentive to keep the plan with that PBM, regardless of whether it's the best choice for the plan.
The ERISA framework
ERISA, the Employee Retirement Income Security Act of 1974, establishes the legal definition of fiduciary in the employee benefits context. Under ERISA, anyone "exercising discretionary authority or control over plan assets" or "rendering investment advice for a fee" is a fiduciary, with specific legal duties:
- Duty of loyalty, act solely in the interest of plan participants and beneficiaries
- Duty of prudence, act with the care, skill, and diligence of a prudent expert under the circumstances
- Duty of diversification, minimize the risk of large losses through prudent diversification
- Duty to follow plan documents, administer the plan according to its written terms
The 2024 Department of Labor Retirement Security Rule expanded the fiduciary definition more explicitly to cover pharmacy benefits and pharmacy benefit consulting in some circumstances. While the rule's specific applicability to pharmacy benefits continues to be litigated, the directional trend is clear: pharmacy benefit advice that influences plan participants' access to drugs is increasingly being treated as fiduciary advice.
Why most pharmacy consultants aren't fiduciaries
Several structural reasons explain why most pharmacy consultants today don't operate as fiduciaries:
1. PBM commissions are still common. Many broker-consultants receive direct commissions from PBMs based on plan spend. These commissions create an incentive to recommend specific PBMs regardless of what's best for the plan.
2. Coalition arrangements blur the line. Some consultants operate under group purchasing or coalition models, where the coalition takes a percentage of rebate dollars in exchange for negotiating "bulk pricing." This puts the consultant on the same side of the table as the PBM, not the plan.
3. "Free" consulting often isn't free. When pharmacy consulting is offered at no cost to the plan sponsor, the consultant is being paid by someone, usually a PBM. The plan sponsor may not see the cost directly, but they're paying it indirectly through inflated PBM administrative fees.
4. Carrier-bundled consulting is built-in. Medical insurance carriers often offer "free" pharmacy consulting bundled with the medical plan. The carrier's pharmacy benefit relationship is, by definition, not independent of the carrier's other business.
The four hidden revenue streams to look for
When evaluating whether a pharmacy consultant is truly a fiduciary, ask about these four revenue streams:
1. Broker-of-record commissions, paid by the PBM to the consultant as a percentage of plan spend
2. Finder's fees, one-time payments from a PBM when the consultant brings a new plan to that PBM
3. Override fees, recurring percentage payments from a PBM based on the consultant's total book of business with that PBM
4. Vendor sponsorships, payments from PBMs, manufacturers, or specialty pharmacies for "education," conferences, or other marketing activities that benefit the consultant
A true fiduciary consultant has none of these. The consultant's only revenue is the fee paid directly by the plan sponsor.
What a written fiduciary attestation looks like
A real fiduciary engagement includes a written attestation in the consulting agreement. The language varies, but a typical attestation reads:
Consultant attests that, with respect to the services provided under this Agreement, Consultant (a) acts in a fiduciary capacity under ERISA Section 3(21), (b) receives no compensation, directly or indirectly, from any pharmacy benefit manager, drug manufacturer, specialty pharmacy, mail-order pharmacy, group purchasing organization, or other vendor in connection with the services provided to Plan Sponsor, (c) maintains a written conflict-of-interest policy available to Plan Sponsor upon request, and (d) will promptly disclose any actual or potential conflict of interest that arises during the term of this Agreement.
If your current consultant won't sign language like this, that's diagnostic. Either they have compensation streams they're not disclosing, or they're operating in a way that doesn't actually meet the fiduciary standard.
Questions to ask your current consultant about their compensation
If you're not sure whether your current consultant is a fiduciary, ask these five questions and pay attention to how they answer:
- "What's your total compensation for working with our plan, including any payments from PBMs, manufacturers, or other vendors?" A fiduciary answers with a single fee number. A non-fiduciary often gives an evasive answer about "industry-standard" or "indirect" compensation.
- "Do you hold broker-of-record status with any PBM?" A fiduciary answers no.
- "Will you sign a fiduciary attestation?" A fiduciary answers yes.
- "What's your conflict-of-interest policy?" A fiduciary has one in writing.
- "How is your compensation affected if we change PBMs?" A fiduciary's compensation doesn't change. A non-fiduciary's often does, sometimes significantly.
Why fiduciary alignment changes outcomes
In practice, fiduciary alignment changes outcomes in two ways. First, the consultant's recommendations reflect what's actually best for the plan rather than what's best for the consultant's other business relationships. Second, the consultant's diligence on the plan's behalf is higher, they have no incentive to soft-pedal a PBM problem because the PBM isn't paying them.
Red flags suggesting your consultant has undisclosed PBM relationships
A few patterns reliably indicate hidden PBM relationships:
- The consultant always recommends the same one or two PBMs across all clients
- The consultant resists open-book audit of their own compensation
- The consultant's fee to the plan sponsor seems suspiciously low for the scope of services
- The consultant is reluctant to compete out the PBM at renewal, citing "switching disruption"
- The consultant attends PBM-sponsored conferences and events at the PBM's expense
- The consultant refuses to sign a fiduciary attestation
Any one of these in isolation isn't dispositive. But the pattern of three or more is a strong signal that hidden compensation is shaping the advice you receive.
The bottom line
Fiduciary pharmacy benefits consulting isn't a marketing label. It's a specific compensation structure backed by specific legal duties under ERISA. The questions above will tell you whether your current consultant operates as a fiduciary in fact, or just calls themselves one. The difference between fiduciary and non-fiduciary consulting is often the difference between a plan that captures its negotiated guarantees and a plan that doesn't.